Advertisement
UK markets closed

  • NIKKEI 225

    38,471.20
    -761.60 (-1.94%)
     

  • HANG SENG

    16,248.97
    -351.49 (-2.12%)
     

  • CRUDE OIL

    85.43
    +0.02 (+0.02%)
     

  • GOLD FUTURES

    2,408.40
    +25.40 (+1.07%)
     

  • DOW

    37,889.53
    +154.42 (+0.41%)
     

  • Bitcoin GBP

    50,597.95
    +124.86 (+0.25%)
     

  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     

  • NASDAQ Composite

    15,918.47
    +33.46 (+0.21%)
     

  • UK FTSE All Share

    4,260.41
    -78.49 (-1.81%)
     
Money:

How to avoid tax creep in retirement

The state pension went up 8.5% in April, but frozen thresholds mean pensioners will be paying more tax

Dynavax Technologies Third Quarter 2022 Earnings: EPS Beats Expectations, Revenues Lag

Simply Wall St
·1-min read

Dynavax Technologies (NASDAQ:DVAX) Third Quarter 2022 Results

Key Financial Results

  • Revenue: US$167.7m (up 55% from 3Q 2021).

  • Net income: US$63.8m (up from US$28.4m loss in 3Q 2021).

  • Profit margin: 38% (up from net loss in 3Q 2021). The move to profitability was primarily driven by higher revenue.

  • EPS: US$0.50 (up from US$0.24 loss in 3Q 2021).

earnings-and-revenue-growth
earnings-and-revenue-growth

All figures shown in the chart above are for the trailing 12 month (TTM) period

Dynavax Technologies EPS Beats Expectations, Revenues Fall Short

Revenue missed analyst estimates by 1.6%. Earnings per share (EPS) exceeded analyst estimates by 31%.

Looking ahead, revenue is expected to decline by 16% p.a. on average during the next 3 years, while revenues in the Biotechs industry in the US are expected to grow by 14%.

ADVERTISEMENT

Performance of the American Biotechs industry.

The company's shares are up 7.1% from a week ago.

Risk Analysis

Before you take the next step you should know about the 2 warning signs for Dynavax Technologies (1 is a bit concerning!) that we have uncovered.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Join A Paid User Research Session
You’ll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here